Handelsbanken Fonder
MRVI icon

Handelsbanken Fonder’s Maravai LifeSciences MRVI Stock Holding History

Handelsbanken Fonder’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-44,600
Closed -$99K – 1548
2025
Q1 		$99K Hold
44,600
– – ﹤0.01% 1520
2024
Q4 		$243K Hold
44,600
– – ﹤0.01% 1491
2024
Q3 		$371K Buy
44,600
+11,700
+36% +$101K ﹤0.01% 1348
2024
Q2 		$236K Buy
32,900
+7,400
+29% +$63.9K ﹤0.01% 1455
2024
Q1 		$221K Hold
25,500
– – ﹤0.01% 1492
2023
Q4 		$167K Buy
25,500
+3,400
+15% +$22K ﹤0.01% 1527
2023
Q3 		$221K Hold
22,100
– – ﹤0.01% 1435
2023
Q2 		$275K Buy
22,100
+2,800
+15% +$37.8K ﹤0.01% 1378
2023
Q1 		$270K Hold
19,300
– – ﹤0.01% 1338
2022
Q4 		$276K Buy
19,300
+2,800
+17% +$44.1K ﹤0.01% 1291
2022
Q3 		$421K Hold
16,500
– – ﹤0.01% 1062
2022
Q2 		$469K Buy
16,500
+300
+2% +$9.5K ﹤0.01% 1062
2022
Q1 		$571K Hold
16,200
– – ﹤0.01% 1106
2021
Q4 		$679K Buy
+16,200
New +$656K ﹤0.01% 1139

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return
PD
Point72 (DIFC) Dubai, United Arab Emirates $1.53B AUM 15.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Handelsbanken Fonder's MRVI Position: Q2 2025 in Review

Handelsbanken Fonder sold out of Maravai LifeSciences (MRVI) in Q2 2025, closing a stake of 44,600 shares — an estimated $99K sold.

Handelsbanken Fonder first reported a position in MRVI in Q4 2021 and held it in 14 quarters. The position peaked at $679K in Q4 2021. 150 funds tracked by Wall St. Rank hold MRVI as of Q2 2025.

  • Handelsbanken Fonder reported no remaining Maravai LifeSciences position as of Q2 2025 after selling out during the quarter.
  • Handelsbanken Fonder sold 44,600 Maravai LifeSciences shares in Q2 2025, an estimated $99K.
  • Handelsbanken Fonder first reported a position in Maravai LifeSciences in Q4 2021 and held it in 14 quarters.
  • Handelsbanken Fonder's Maravai LifeSciences position peaked at $679K in Q4 2021.
  • 150 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2025.

Based on Handelsbanken Fonder's 13F filing for Q2 2025, filed 12 Aug 2025.